Skip to main content
HighlightsHighlights Archive

Fleming Initiative boosted by £45m GSK investment

By May 22, 2024No Comments

GSK will become the first partner of the new Imperial-led Fleming Initiative, which aims to tackle antimicrobial resistance globally.

Global biopharma company GSK will become the first founding partner of the Fleming Initiative, an innovative and collaborative new approach led by Imperial College London and Imperial College Healthcare NHS Trust and to tackle antimicrobial resistance (AMR) around the world.

A £45m pledge from GSK was announced by Professor the Lord Darzi of Denham, Executive Chair of the Fleming Initiative, and GSK CEO Emma Walmsley, at an event celebrating global efforts and initiatives to tackle AMR convened by the UK Department for Health and Social Care and the Royal Society.

The pledge will support the Fleming Initiative’s unique and transformative approach and will help bring together world-class expertise in science, technology, policy and behavioural science alongside clinical experience, through a global network of centres that will find, test, and scale solutions to AMR.

At the heart of the Fleming Initiative will be the Fleming Centre, set to open at St Mary’s Hospital in 2028 and helping to mark the centenary of the discovery of penicillin at the hospital by Sir Alexander Fleming. At the Centre, scientists will work alongside clinicians, patients, members of the public and policy makers to scope, test and scale solutions. The Fleming Centre will work closely with regional networks of centres in strategic locations around the world to catalyse worldwide action.

Ben Kemp